Antimicrobial Photodynamic Activity of the Zn(II) Phthalocyanine RLP068/Cl Versus Antimicrobial-Resistant Priority

Ilaria Baccani1,2, Sara Cuffari1,2, Francesco Giuliani3

  • 1Department of Experimental and Clinical Medicine (DMSC), University of Florence, Largo Brambilla, 3, 50134 Florence, FI, Italy.

Insights

Antimicrobial photodynamic therapy (aPDT) using RLP068/Cl shows potent activity against multidrug-resistant bacteria and Candida species. This approach offers a promising strategy for treating infections where conventional therapies fail.

Area of Science:

  • Microbiology
  • Photomedicine
  • Antimicrobial Resistance

Background:

  • Antimicrobial resistance (AMR) is a growing global health threat, limiting treatment options.
  • Novel therapeutic strategies are urgently needed to combat resistant pathogens.
  • Antimicrobial photodynamic therapy (aPDT) offers a multitarget mechanism with low resistance development risk.

Purpose of the Study:

  • To evaluate the antimicrobial efficacy of RLP068/Cl-mediated aPDT against a large panel of clinical multidrug-resistant (MDR) strains.
  • To assess the activity against Gram-negative bacteria, Gram-positive bacteria, and Candida species.
  • To determine the potential of RLP068/Cl-mediated aPDT as a treatment for MDR infections.

Main Methods:

  • Tested the photosensitizer RLP068/Cl combined with a 630 nm red LED light source.
  • Evaluated activity against a diverse collection of clinical multidrug-resistant bacterial and Candida strains.
  • Determined the range of bactericidal concentrations (RCs) for different microbial types.

Main Results:

  • RLP068/Cl-mediated aPDT demonstrated significant microbicidal activity against all tested strains, irrespective of resistance phenotype.
  • Potent activity was observed against Gram-positive bacteria (RCs 0.05-0.1 µM).
  • Lower concentrations were required for Gram-positive bacteria compared to Candida and Gram-negative species (RCs 5-20 µM).

Conclusions:

  • RLP068/Cl-mediated aPDT is effective against a broad spectrum of MDR clinical isolates.
  • This therapy shows particular promise for Gram-positive bacterial infections.
  • aPDT represents a viable therapeutic option for localized MDR infections, especially when standard treatments are ineffective.